|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||404.5 g/mol g·mol−1|
|3D model (JSmol)|
PX-3 (also known as APP-CHMINACA) is an indazole-based synthetic cannabinoid. It is a potent agonist of the CB1 receptor with a binding affinity of Ki = 47.6 nM and was originally developed by Pfizer in 2009 as an analgesic medication.
The acronym 'APP' signifies the 'amino', 'phenyl' and 'propanone' elements of the structure. Three related compounds, PX-1 (5F-APP-PICA, SRF-30), PX-2 (5F-APP-PINACA, FU-PX) and APP-FUBINACA were reported by the EMCDDA in late 2014.
Sweden's public health agency suggested to classify APP-CHMINACA as hazardous substance on June 1, 2015.
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|